Bristol-Myers Squibb (BMY) Misses Q3 EPS by 2c, Beats on Revenues; Lowers FY17 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Bristol-Myers Squibb (BMY) Reports EMA Validates Type II Variation Application for Opdivo (Nivolumab)
October 30, 2017 7:00 AM EDTBristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) to include the treatment of patients with melanoma who are at high risk of disease recurrence following complete surgical resection. Validation of the... More
SunTrust Robinson Humphrey Upgrades Bristol-Myers Squibb Co. (BMY) to Buy
October 30, 2017 6:47 AM EDTSunTrust Robinson Humphrey upgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Hold to Buy with a price target of $75.00 (from $55.00).
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More
Bristol-Myers Squibb (BMY) Weakness Unwarranted - JPMorgan
October 26, 2017 1:04 PM EDTJPMorgan maintains Overweight on Bristol-Myers Squibb Co. (NYSE: BMY).
Analyst Chris Schott says the overall results for Q3 were solid and that the weakness in the stock today is unwarranted. The analyst reminds client the next catalyst he sees for upside... More
